The SUB-urothelial DUrvalumab InjEction-1 (SUBDUE-1) trial: first-in-human trial in patients with bladder cancer.

Dickon HayneKatherine OngNicole SwarbrickSteve P McCombieAndrew MoeCynthia HawksPravin ViswambaramCiara ConduitElizabeth LiowLisa SpaldingJayne LimThomas FergusonKatie MeehanIan D DavisAndrew D Redfern

Published in: BJU international (2024)

Sub-urothelial injection of durvalumab is feasible and safe without immune-related AEs and shows local immunological effects.

Keyphrases

phase iii
study protocol
high grade
phase ii
clinical trial
endothelial cells
urinary tract
ultrasound guided
induced pluripotent stem cells
pluripotent stem cells
drug induced
double blind
muscle invasive bladder cancer